Published Outcomes
19,801 Patients
Published ASMBS scientific presentation.
- 19,801 patients analyzed
- Average BMI 42.3
- Average stay 22.4 hours
- 30-day morbidity 1.2%
- No mortalities reported
Educational Health Resource
Learn about GLP-1 medications, bariatric surgery, metabolic surgery, and other evidence-based approaches to weight management.
Educational information designed to support informed healthcare decisions. GLPSurgery.com does not declare any single treatment superior to another. We explain how the available options work, how they compare, how they may be combined, and what to ask a qualified clinician about your specific situation.
Neutral & evidence-informed
Clinician-reviewed
Multidisciplinary lens
Long-term focus
Who publishes this site
GLPSurgery.com is an educational publication that supports coordinated evaluation with the clinical team at the Obesity Control Center (OCC). We disclose this relationship on every page. Editorial decisions, sources, and reviewer bylines follow the policies linked in the footer.
How it works
From first message to long-term care
Every patient's path through evaluation is different. These are the general steps most people experience — educational only, not a substitute for personalized medical advice.
1. First message
Reach out via the form, WhatsApp, or the AI assistant. No medical questions are answered by AI — a coordinator responds.
2. Records & goals
Share your current medications, weight history, comorbidities, and what you're hoping to accomplish. All communication is confidential.
3. Clinical evaluation
A physician-led multidisciplinary review discusses appropriate options — medication, endoscopic, surgical, or combined.
4. Personalized plan
You receive a written summary of options with risks, follow-up requirements, and estimated costs before any decision is made.
5. Long-term support
Follow-up, nutrition guidance, and ongoing metabolic monitoring — regardless of which pathway you choose.
Authority & Evidence
Evidence Matters
Patients deserve access to published outcomes, accreditation information, and evidence-based resources when evaluating treatment options.
Joint Commission International
JCI Accredited Program
Joint Commission International Accredited Program — verifiable through the official JCI directory.
Verify AccreditationSRC Center of Excellence
Accredited Since 2010
SRC Accredited Center of Excellence since 2010 — listed in the Surgical Review Corporation public directory.
Verify Source25+ Years Experience
Bariatric & Metabolic Surgery
More than 25 years of bariatric and metabolic surgery experience at a high-volume international referral center.
Learn MoreAccreditation status is maintained by the issuing organizations and may change over time; please re-verify at the official links. Educational content only — individual outcomes vary and treatment decisions require evaluation by qualified healthcare professionals.
Care pathways
Where would you like to start?
Four journey stages, grouped by where you are today. Every link leads to educational content — no medical decisions are made online.
Understand
Learn what the options are
Start here if you want the facts about GLP-1 medications, surgery, and metabolic disease.
Plan
Weigh cost and choose a program
Tools that help you compare providers, estimate cost, and prepare for a real conversation.
Treat
Explore treatment options in depth
Detailed pages on each procedure and comparative deep-dives.
Travel & support
If care means traveling
Logistics, packages, and geo-specific information for patients considering coordinated international care.
Content reviewed by healthcare professionals experienced in obesity medicine, bariatric surgery, and metabolic health. Each article carries a "Last reviewed" date and is updated on a regular schedule.
Learn
What are GLP-1 medications?
GLP-1 receptor agonists are a class of medications used in the treatment of type 2 diabetes and, in certain formulations, chronic weight management. They are designed to mimic incretin hormones produced naturally in the gut and act on multiple pathways related to appetite and glucose regulation.
Mechanism of action
GLP-1 receptor agonists bind to receptors found in the pancreas, gastrointestinal tract, and central nervous system. They slow gastric emptying and act on satiety pathways in the brain, helping reduce hunger and food intake at therapeutic doses. Tirzepatide also activates GIP receptors, a related incretin pathway.
Appetite regulation
By enhancing post-meal satiety and reducing perceived hunger, these medications can make a calorie-deficit eating pattern more tolerable for many patients. Effects are pharmacologic and persist while the medication is being administered at a therapeutic dose.
Blood sugar effects
GLP-1 receptor agonists enhance glucose-dependent insulin secretion and reduce glucagon release, supporting improved glycemic control in patients with type 2 diabetes. Hypoglycemia risk when used as monotherapy is generally low, but increases when combined with insulin or sulfonylureas.
Commonly discussed medications
Examples include semaglutide (Ozempic for type 2 diabetes, Wegovy for chronic weight management), tirzepatide (Mounjaro for type 2 diabetes, Zepbound for chronic weight management), and earlier agents such as liraglutide. Approved indications, dosing, and access differ by product and region.
How they are taken
Most current weight-management agents are administered as a once-weekly subcutaneous injection that patients self-administer. An oral semaglutide formulation also exists. Dose is typically titrated upward over several weeks to support tolerability.
Things to discuss with a clinician
Personal and family history, current medications, prior cancers or thyroid conditions, pregnancy plans, history of pancreatitis or severe gastrointestinal disease, and insurance or affordability considerations are typically reviewed before starting any GLP-1 medication.
Learn
What is bariatric and metabolic surgery?
Bariatric and metabolic surgery describes a group of procedures that modify gastrointestinal anatomy and neurohormonal signaling to support sustained weight reduction and improvements in metabolic conditions. Endoscopic procedures are less invasive options that reshape the stomach without external incisions.
Sleeve gastrectomy
One of the most commonly performed procedures worldwide. A portion of the stomach is removed, leaving a smaller, tubular ('sleeve-shaped') stomach. This reduces gastric volume and influences hormones involved in hunger and satiety.
Mini gastric bypass
One-anastomosis gastric bypass creates a smaller stomach pouch with a single intestinal connection. It is technically less complex than Roux-en-Y gastric bypass and has its own risk, benefit, and follow-up profile.
Revisional surgery
Performed after an initial bariatric procedure — for example, to address insufficient response, weight regain, reflux, or anatomic considerations. Revisional procedures are technically more complex and require experienced teams.
Endoscopic sleeve gastroplasty (ESG)
An endoscopic procedure performed through the mouth, without external incisions, in which sutures are placed inside the stomach to reduce its volume. ESG is generally considered less invasive than surgical sleeve gastrectomy.
Roux-en-Y gastric bypass
Creates a small stomach pouch and reroutes a portion of the small intestine. Has the longest evidence base in bariatric surgery, with extensive published data on weight and metabolic outcomes.
What evaluation involves
Accredited programs use multidisciplinary evaluation — surgery, medicine, nutrition, behavioral health — to discuss whether a procedural option is appropriate and which one best fits a patient's clinical picture, anatomy, and goals.
Published outcomes
Published OCC Outcomes Data
A published ASMBS scientific presentation analyzed outcomes from 19,801 bariatric surgery patients treated through a standardized program following ASMBS guidelines over a 20-year period (April 2000 – October 2021).
19,801
Patients analyzed
42.3
Average BMI
22.4 hrs
Average stay
1.2%
30-day morbidity
0
Mortalities reported
76.18%
Average %EWL at 2 years
Published outcomes reflect the study population and time period analyzed. Individual outcomes vary and cannot be guaranteed. Candidacy for any surgical or medical treatment must be determined by a qualified clinician after individual evaluation.
Treatment pathways
Understanding different treatment pathways
There is no single 'best' pathway that applies to every patient. Below are categories of evidence-based tools clinicians may consider — alone, in sequence, or in combination — when caring for adults living with obesity or related metabolic conditions.
Lifestyle interventions
Nutrition, physical activity, sleep, stress, and behavioral patterns are foundational across every pathway. They are not replaced by medication or surgery.
Medical management
Care for related conditions — type 2 diabetes, hypertension, dyslipidemia, fatty liver disease, sleep apnea — is part of comprehensive treatment.
GLP-1 medications
Pharmacotherapy that acts on appetite and glucose-regulation pathways, used at therapeutic doses with appropriate monitoring.
Endoscopic procedures
Less invasive options such as endoscopic sleeve gastroplasty (ESG) that reshape the stomach without external incisions.
Bariatric & metabolic surgery
Procedures that modify gastrointestinal anatomy and neurohormonal signaling, evaluated within multidisciplinary programs.
Combined and sequential approaches
Pharmacologic, endoscopic, and surgical tools may be used together or sequentially as part of an individualized plan.
Read more on each pathway
GLP-1 vs Surgery
A balanced comparison across mechanism, follow-up, risks, costs, and lifestyle.
Read articleWhen GLP-1s Are Stopped
Appetite, weight regain risk, behavioral factors, and long-term planning.
Read articleCombined Use
Preoperative use, postoperative use, weight-regain management, integrated pathways.
Read articleWhich Pathway?
Factors clinicians may evaluate — BMI, comorbidities, history, preferences.
Read articleMetabolic Disease & Weight
Type 2 diabetes, insulin resistance, fatty liver, hypertension, sleep apnea.
Read articleLong-Term Costs
Categories of cost across medication, surgical, and follow-up pathways.
Read articleBalanced comparison
GLP-1 therapy vs surgery: side-by-side
The table below compares the two pathways across common decision dimensions. It is not a recommendation. Specialty society guidance does not declare one pathway universally superior; the most appropriate option is individualized.
Dimension
GLP-1 receptor agonists
Bariatric / metabolic surgery
Mechanism
Mimics incretin hormones; acts on appetite and glucose-regulation pathways while the medication is taken.
Modifies gastrointestinal anatomy and downstream neurohormonal signaling; anatomic and hormonal changes persist.
Follow-up
Ongoing prescriber visits, dose titration, periodic labs, continuous medication supply.
Multidisciplinary preoperative evaluation; staged postoperative recovery; lifelong nutritional follow-up and periodic labs.
Potential outcomes
Phase-3 trials at therapeutic doses report average total body-weight reductions in the mid-teens to low-twenties percent over ~68–72 weeks. Improvements in glycemia, blood pressure, and lipids have also been reported. Individual response varies.
Long-term cohorts and trials (e.g., STAMPEDE, SLEEVEPASS, SM-BOSS) report meaningful and often durable weight reductions and improvements in conditions such as type 2 diabetes, hypertension, and sleep apnea for many patients. Individual response varies.
Risks
Most commonly gastrointestinal effects (nausea, vomiting, diarrhea, constipation). Other considerations include gallbladder events, rare pancreatitis, and changes in lean body mass. Specific contraindications apply.
As with any major procedure: bleeding, infection, anastomotic or staple-line complications, venous thromboembolism, nutritional deficiencies, dumping syndrome (with bypass), and procedure-specific complications.
Costs
Recurring monthly cost; multi-year total accumulates and depends on product, dose, insurance, and patient-assistance programs.
Larger one-time episode-of-care cost plus ongoing follow-up. Self-pay and international packages exist; itemized estimates are encouraged.
Long-term considerations
Effect depends on continued use. Discontinuation is associated with appetite return and substantial weight regain in published trial extensions.
Durable for many patients; a subset experience insufficient response or later regain. Long-term nutritional and behavioral follow-up supports outcomes.
References for the figures cited here are available on the References page and include ASMBS, ADA Standards of Care, AACE guidance, and peer-reviewed trial literature.
Integrated pathways
Can GLP-1 medications and surgery be used together?
Society guidance increasingly frames obesity as a chronic, relapsing condition that benefits from longitudinal, multidisciplinary care. Within that framework, GLP-1 therapy and surgical procedures are tools that may be applied at different stages — sometimes sequentially, sometimes together.
Preoperative use
In some patients, GLP-1 therapy is used in the months leading up to surgery to support weight reduction, improve glycemic control, or address hepatic steatosis. Anesthesia teams provide guidance on perioperative timing.
Postoperative use
Pharmacotherapy may be considered alongside continued nutritional and behavioral support after surgery when additional weight reduction or metabolic improvement is desired.
Weight regain management
If weight regain occurs after a procedure, reintroducing or initiating GLP-1 therapy is one option a clinician may consider, alongside behavioral re-engagement and evaluation for anatomic causes.
Individualized planning
Whether to combine, sequence, or stay with a single modality is a clinical decision based on response, tolerability, comorbidities, and patient preferences.
For more depth, see Can GLP-1 Medications and Surgery Work Together?
Objective overview
Potential benefits and limitations
Every evidence-based treatment has potential benefits and limitations. The summaries below are educational and not a recommendation for or against any specific therapy.
GLP-1 receptor agonists
Potential benefits
- Non-surgical, can be initiated, paused, or stopped under clinician guidance.
- Acts on appetite and glycemic pathways; supports lifestyle change for many patients.
- Has demonstrated improvements in body weight, glycemic measures, and certain cardiovascular outcomes in published trials.
- Multiple agents and doses; allows individualized titration.
Potential limitations
- Effects depend on continued use; discontinuation is associated with appetite return and weight regain.
- Gastrointestinal side effects are common, especially during dose escalation.
- Recurring cost; insurance coverage for weight management varies and may change.
- Specific contraindications and warnings apply (see prescribing information).
Bariatric & metabolic surgery
Potential benefits
- Outcomes are durable for many patients in long-term published cohorts.
- Associated with improvements in type 2 diabetes, hypertension, sleep apnea, and other conditions in a substantial proportion of patients.
- One-time procedural episode rather than ongoing pharmacologic dosing.
- Multidisciplinary follow-up structure built around long-term care.
Potential limitations
- Surgical risks are real, including bleeding, infection, anastomotic or staple-line complications, and procedure-specific events.
- Lifelong nutritional follow-up and periodic micronutrient labs are required.
- A subset of patients experience insufficient initial response or later weight regain.
- Access, eligibility, and recovery time considerations apply.
Safety
Risks and considerations
Both pharmacologic and surgical pathways carry real risks. A qualified clinician reviews these in the context of an individual patient's medical history and current health status.
GLP-1 receptor agonists
- Gastrointestinal effects: nausea, vomiting, diarrhea, and constipation are the most commonly reported, especially during dose escalation; effects often improve with time and titration.
- Other reported considerations: gallbladder events, rare pancreatitis, changes in lean body mass, and injection-site reactions.
- Adherence: consistent administration and follow-up are part of safe use; missed doses or interruptions affect both efficacy and tolerability.
- Contraindications and warnings: include personal or family history of medullary thyroid carcinoma, MEN-2, known serious hypersensitivity, and additional cautions described in the product label.
Bariatric & metabolic surgery
- Surgical risks: bleeding, infection, anastomotic or staple-line complications, venous thromboembolism, and procedure-specific events. In accredited centers, 30-day mortality for primary bariatric surgery has been reported in the low single digits per 1,000 in contemporary registry data.
- Nutritional considerations: protein, hydration, vitamin, and mineral practices; periodic micronutrient laboratory monitoring is standard follow-up.
- Recovery: staged dietary progression, activity restrictions during the early postoperative period, and clinician-guided return to normal activities.
- Long-term considerations: reflux, dumping syndrome (in bypass procedures), and possibility of revisional procedures in a subset of patients.
Candidacy
Who may not be a candidate?
Not every patient is an immediate candidate for every pathway, and that is part of safe, individualized care. The factors below are general educational examples — only a qualified clinician can determine candidacy after a complete evaluation.
Medical considerations
- Uncontrolled or active medical conditions that increase procedural or medication risk and have not yet been optimized.
- Active, untreated substance use disorders or eating disorders that require stabilization first.
- Pregnancy, planned pregnancy in the near term, or breastfeeding — relevant to several pharmacologic options.
- Personal or family history of medullary thyroid carcinoma, MEN-2, or known hypersensitivity to specific GLP-1 agents.
- Severe gastrointestinal disease, prior complex abdominal surgery, or anatomic findings requiring further evaluation before a procedural pathway.
Lifestyle and readiness factors
- Inability or unwillingness to engage in long-term nutritional and behavioral follow-up.
- Significant logistical barriers — access to follow-up labs, prescriber visits, or postoperative care.
- Expectations of a single, rapid 'cure' rather than long-term chronic-disease management.
- Unresolved psychosocial stressors that a behavioral health clinician recommends addressing first.
Alternative or interim options
- Structured medical weight management, including non–GLP-1 pharmacotherapy when appropriate.
- Lifestyle programs combining nutrition, physical activity, sleep, and behavioral support.
- Treatment of related conditions — type 2 diabetes, hypertension, sleep apnea, fatty liver disease — through standard medical care.
- Endoscopic options (such as ESG) for patients who are not pursuing surgery at this time.
Situations requiring further evaluation
- Patients with prior bariatric procedures considering revisional options.
- Adolescents and older adults, where eligibility criteria and risk–benefit profiles differ.
- Patients with complex cardiac, pulmonary, renal, or hepatic disease who benefit from specialist input first.
- Patients with a BMI near commonly discussed thresholds, where individualized assessment is especially important.
Consultation roadmap
What to expect during your initial consultation
A first consultation is an evaluation, not a sales appointment. The structure below is a general educational description of what a thorough metabolic or bariatric consultation typically includes.
- 1
Medical history review
Personal and family history, current and prior medications (including GLP-1 therapies), prior weight-management attempts, prior surgeries, allergies, mental health history, and obesity-related conditions such as type 2 diabetes, hypertension, sleep apnea, fatty liver disease, and reflux.
- 2
Physical and functional evaluation
Height, weight, BMI, vital signs, and a focused physical examination. Functional capacity, mobility, and prior exercise history are reviewed in the context of recovery and long-term planning.
- 3
Diagnostic testing
Depending on clinical context, laboratory studies (metabolic panel, lipid profile, HbA1c, vitamin and mineral levels), and additional testing such as cardiology, pulmonology, sleep, or gastroenterology evaluation may be recommended.
- 4
Goals and expectations
An honest discussion of what each pathway can and cannot achieve, including realistic ranges of outcome, durability, and the role of long-term lifestyle and follow-up. The goal is informed decision-making, not persuasion.
- 5
Risk discussion
Specific risks of pharmacologic therapy, endoscopic options, and surgical procedures relevant to the patient's situation, including contraindications, less common complications, and recovery considerations.
- 6
Treatment options and alternatives
Review of the full range of reasonable options — lifestyle interventions, medical management, GLP-1 therapy, endoscopic procedures, and surgical procedures — along with situations where waiting or further evaluation is appropriate.
- 7
Plan and shared decision-making
If the patient and clinical team move forward, the plan includes preparation steps, additional consults, follow-up structure, and a clear description of what is and is not included. Patients are encouraged to ask questions and to take time before deciding.
Reasonable alternatives
Treatment alternatives
There is no single 'best' option for every patient. Reasonable alternatives below are described objectively, without superiority claims. Eligibility and the right choice are individualized clinical decisions.
Structured lifestyle programs
Potential benefits: Foundational for every pathway; no procedure or prescription required; addresses root behaviors.
Potential limitations: Sustained results are challenging for many patients; obesity is a chronic, relapsing condition with biological drivers beyond willpower.
Key differences: Does not act directly on incretin pathways or anatomy.
Non–GLP-1 medical therapy
Potential benefits: Several FDA-approved options exist; may be appropriate when GLP-1 therapy is contraindicated, not tolerated, or not accessible.
Potential limitations: Average weight reduction is generally lower than GLP-1 receptor agonists in published trials; side-effect profiles vary.
Key differences: Acts on different pathways (e.g., norepinephrine/serotonin, lipase inhibition, opioid receptor modulation).
GLP-1 receptor agonists
Potential benefits: Non-surgical; meaningful average weight reduction in trials; cardiometabolic benefits in specific populations.
Potential limitations: Effects depend on continued use; gastrointestinal side effects common; recurring cost; specific contraindications apply.
Key differences: Pharmacologic effect on appetite and glucose regulation; reversible on discontinuation.
Endoscopic procedures (e.g., ESG)
Potential benefits: Less invasive than surgery; no external incisions; shorter recovery for many patients.
Potential limitations: Durability and outcome ranges differ from surgical options; not all patients are candidates; coverage varies.
Key differences: Reshapes the stomach endoscopically without altering intestinal anatomy.
Bariatric and metabolic surgery
Potential benefits: Durable outcomes for many patients in long-term cohorts; improvements in type 2 diabetes and other conditions; structured multidisciplinary follow-up.
Potential limitations: Surgical risks; lifelong nutritional follow-up; insufficient response or later regain in a subset of patients.
Key differences: Anatomic and neurohormonal changes that persist beyond a single course of treatment.
Watchful waiting and reassessment
Potential benefits: Appropriate when further evaluation is needed, when a patient is not ready, or when other conditions should be addressed first.
Potential limitations: Untreated obesity and related conditions can progress over time.
Key differences: A planned pause with defined re-evaluation, not an absence of care.
Recovery roadmap
Recovery timeline
Recovery varies by individual, by procedure, and by the specific pharmacologic regimen. The general framework below is educational and is not a substitute for the personalized plan your clinical team provides.
Day 1
Immediate post-procedure period. Monitored recovery, hydration, early mobilization, and clinician-guided pain and nausea management. For pharmacologic starts: education on injection technique, expected gastrointestinal effects during titration, and warning signs.
Week 1
Surgical patients typically follow a liquid diet phase, prioritize protein and hydration, and gradually increase walking. Pharmacologic patients monitor early tolerability and follow titration instructions.
Week 2
Transition to pureed or soft foods after surgery in most programs; continued activity progression. For medication, ongoing dose titration with structured prescriber check-ins.
Month 1
Most surgical patients progress toward soft solids and resume light daily activities. Lab work, nutrition reviews, and behavioral check-ins begin. For medications, the first dose escalations are typically complete and adherence patterns are reviewed.
Month 3
Return to most normal activities for surgical patients; structured nutrition, physical activity, and behavioral plans are reinforced. For pharmacologic therapy, response is reassessed and adjustments are considered.
Month 6
Mid-term reassessment of weight, metabolic markers, and quality of life. Long-term plan reviewed across both pathways; adjustments to nutrition, activity, behavioral support, or pharmacotherapy may be made.
Year 1 and beyond
Long-term follow-up — labs, micronutrient monitoring after surgery, behavioral and nutritional support, and reassessment of any pharmacologic regimen. Obesity is a chronic, relapsing condition that benefits from continuous care, not a time-limited intervention.
Patient journey
What the patient journey typically looks like
From initial inquiry to long-term follow-up, well-organized care follows a predictable structure. Each step exists to support an informed, safe, and durable plan.
- Step 1
Inquiry
Initial contact and review of general educational information. No clinical relationship is established at this stage.
- Step 2
Consultation
Comprehensive medical, nutritional, and behavioral history with a qualified clinician.
- Step 3
Evaluation
Targeted diagnostic testing, specialist input as needed, and review of risks and alternatives.
- Step 4
Treatment planning
Shared decision-making and a written plan that includes preparation, follow-up structure, and what is and is not included.
- Step 5
Procedure or treatment
Pharmacologic initiation, endoscopic procedure, or surgery delivered within an accredited program with clear safety protocols.
- Step 6
Recovery
Stage-based nutritional and activity progression, monitoring for complications, and behavioral support.
- Step 7
Long-term follow-up
Ongoing clinical visits, labs, behavioral and nutritional support, and reassessment of the treatment plan over years, not weeks.
Physician perspective
Expert insight
The following educational perspectives summarize common themes from clinicians who care for patients across both pharmacologic and surgical pathways. They are not individual medical advice.
"One of the most common misconceptions patients have is that GLP-1 medications and surgery are competing options. In practice, they are different tools for a chronic condition, and many patients benefit from thoughtful use of more than one over time."
"Patients frequently ask, 'Which one is best?' The honest answer is that the right pathway is the one that fits an individual patient's medical situation, goals, and circumstances. The same patient may make different decisions at different points in life."
"What often matters most over five and ten years is not the initial choice, but the strength of follow-up — nutrition, behavioral support, labs, and re-engagement when life changes."
Objective criteria
Why patients choose this program
The criteria below are objective and patient-facing. They are intended as decision-support, not promotional claims. We do not guarantee outcomes.
JCI-listed organization
Obesity Control Center is listed by Joint Commission International as “Obesity Control Center (Cyntar),” Tijuana, Mexico.
Verify source →SRC-accredited provider listing
Listed by Surgical Review Corporation as an SRC-accredited provider.
Verify source →5-year follow-up program
OCC states that all surgeries include a structured 5-year follow-up program — framing care as long-term, not a single episode.
Verify source →Published 19,801-patient dataset
An ASMBS scientific presentation analyzed outcomes from 19,801 bariatric surgery patients treated through a standardized program following ASMBS guidelines.
Verify source →SRC Master Surgeon recognition
OCC publicly states that Dr. Ariel Ortiz and Dr. Arturo Martínez hold Master Surgeon recognition by Surgical Review Corporation.
Verify source →Education-first approach
Patients are given the information needed to make an informed decision, including objective discussion of alternatives and reasons not to proceed.
Multidisciplinary care
Surgical, medical, nutritional, and behavioral expertise within a coordinated pathway, rather than a single-provider transaction.
International patient coordination
Written summaries and structured handoff to home-country clinicians for patients who travel for evaluation or treatment.
Long-term
Long-term weight management
No treatment works in isolation. Whether a patient is using GLP-1 medications, has undergone a procedure, or is using both at different times, sustained outcomes are supported by ongoing attention to nutrition, activity, behavioral health, and follow-up.
Nutrition
Protein adequacy, fiber, hydration, and a sustainable eating pattern support outcomes across every pathway. Individualized guidance from a registered dietitian or qualified nutrition professional is helpful.
Physical activity
Regular movement — combining aerobic activity and resistance training to preserve lean mass — is associated with better long-term outcomes regardless of whether medication, surgery, or both are part of care.
Behavioral support
Eating patterns, stress, sleep, and other modifiable factors influence response and durability. Many accredited programs integrate behavioral health into routine care.
Follow-up
Scheduled clinical visits, labs, and reassessment of treatment response are part of chronic-disease care. Society guidance frames obesity as a long-term condition that benefits from continuous follow-up.
Network positioning
Part of the OCC & Ariel Center Metabolic Health Network
GLPSurgery.com is an educational property associated with the OCC & Ariel Center Metabolic Health Network. This relationship is disclosed transparently. Editorial standards described in our Editorial Policy apply regardless of any commercial relationship, and editorial decisions are not driven by advertisers or sponsors.
Multidisciplinary care
Network programs combine surgical, medical, nutritional, and behavioral expertise within a coordinated pathway.
Long-term follow-up
Programs in the network describe obesity as a chronic, relapsing condition that benefits from longitudinal care.
International patient support
For patients who travel for evaluation, network programs provide written summaries and coordination with home-country clinicians.
See Editorial Policy for our full statement on independence and disclosures.
Explore Treatment Pathways
Continue your research with focused educational resources covering medication, endoscopic treatment, bariatric surgery, and care after weight regain.
- Compare Weight-Loss ProceduresCompare medication, endoscopic treatment, gastric sleeve, bypass, and revision procedures.Compare treatment options
- Endoscopic Sleeve GastroplastyLearn how ESG works and how it compares with GLP-1 medication and bariatric surgery.Explore ESG
- Treatment After Bariatric SurgeryReview options for weight regain, reflux, inadequate results, or medication use after previous surgery.Explore post-surgical options
Some related educational resources share a publishing network. Links are selected according to topic relevance. See our Network & Editorial Disclosure.
FAQ
Frequently asked questions
Educational answers to common questions. For a longer reference list of 30+ questions across eight categories, see the full FAQ.
See the full FAQ library for additional questions and category-level depth.
References
References and clinical guidelines
Educational content on this page is informed by guidance from leading professional and government bodies and by peer-reviewed bariatric and metabolic literature.
Sources
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH / NIDDK) — Weight Management
- World Health Organization — Obesity and overweight
- American Society for Metabolic and Bariatric Surgery (ASMBS)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- ASMBS/IFSO 2022 Indications for Metabolic and Bariatric Surgery
- American Diabetes Association — Standards of Care in Diabetes
- American Association of Clinical Endocrinology (AACE) — Clinical Guidance
- U.S. Food & Drug Administration — Prescribing Information lookup
Trial-specific citations (STEP, SURMOUNT, STAMPEDE, SLEEVEPASS, SM-BOSS, and others) are listed on the References page.
Editorial oversight
Medical Review & Clinical Oversight
The educational content on this website is reviewed for medical accuracy, clarity, and patient safety by experienced bariatric and metabolic surgery professionals. The purpose of this review is to help ensure that information about obesity treatment, bariatric surgery, metabolic health, revisional surgery, endoscopic procedures, GLP-1 medications, and long-term follow-up is presented responsibly and without exaggerated claims.
Medical Reviewers
Reviewer
Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS
Bariatric & Metabolic Surgeon
Founder and Director, Obesity Control Center
Dr. Ariel Ortiz Lagardere is a bariatric and metabolic surgeon with extensive experience in minimally invasive weight-loss surgery, metabolic disease treatment, international patient care, and surgical education. Public professional profiles describe him as board-certified in Mexico, a Fellow of the American College of Surgeons, a Fellow of the American Society for Metabolic and Bariatric Surgery, and an SRC-recognized Master Surgeon in Metabolic and Bariatric Surgery.
Reviewer
Dr. Arturo Martinez Gamboa, MD
Bariatric & Metabolic Surgeon
Obesity Control Center
Dr. Arturo Martinez Gamboa has been affiliated with Obesity Control Center since 2001. His publicly available professional biography describes advanced laparoscopic and bariatric training at Hospital Ramón y Cajal in Madrid, Spain. Surgical Review Corporation sources identify him as an SRC-accredited Master Surgeon in Metabolic & Bariatric Surgery and Bariatric Revisional Surgery.
Reviewer
Dr. Helmuth Billy, MD
Bariatric & Revisional Surgery Specialist
Ventura, California
Dr. Helmuth Billy is a bariatric surgeon specializing in laparoscopic bariatric surgery, revisional bariatric surgery, and multidisciplinary weight-loss care. Public ASMBS meeting biographies describe him as being in private practice since 1997, actively practicing bariatric surgery since 2000, serving as medical director at two MBSAQIP hospitals, and having a clinical interest in weight regain and revisional surgery.
Editorial Review Process
All medical content is periodically reviewed for accuracy, relevance, readability, and consistency with current medical knowledge and accepted bariatric and metabolic surgery principles. Content is intended to support informed decision-making and does not replace consultation with a qualified healthcare professional.
Educational Disclaimer
This website provides general educational information only. It does not provide medical advice, diagnosis, treatment recommendations, or guarantees of outcome. Candidacy for any medical, surgical, endoscopic, or medication-based treatment must be determined by a qualified healthcare professional after an individual evaluation.
Last reviewed: June 2026
References
Educational content on this site is informed by guidance from leading professional and government bodies, and by peer-reviewed bariatric and metabolic literature.
- American Society for Metabolic and Bariatric Surgery (ASMBS)
- International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO)
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH / NIDDK)
- American Diabetes Association — Standards of Care
- American Association of Clinical Endocrinology (AACE) — Obesity & Metabolic Guidelines
- ASMBS/IFSO 2022 Indications for Metabolic and Bariatric Surgery
Coordinated evaluation
Request educational information about a coordinated metabolic evaluation.
Share a few details and a patient coordinator will respond within one business day with general educational information about evaluation pathways. Submitting this form is not a request for medical advice and does not establish a clinician–patient relationship.
Reviewed by
Dr. Ariel Ortiz Lagardere, MD, FACS, FASMBS
Bariatric & Metabolic Surgeon · Founder, Obesity Control Center
Last reviewed: June 2026
Sources
Educational claims on this page are supported by independent guidelines, peer-reviewed evidence, and verifiable accreditation listings. See Sources & Verification and Science & Evidence.
Medical notice. This content is educational only and does not replace professional medical advice. Do not start, stop, or change GLP-1 medication without consulting your physician.